Consequences of Canada’s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access

Nigel Rawson

Open source

DOI
10.2147/ceor.s567932
Published
2025-12
Container
ClinicoEconomics and Outcomes Research
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2147/ceor.s567932,
  title = {Consequences of Canada’s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access},
  author = {Nigel Rawson},
  year = {2025},
  journal = {ClinicoEconomics and Outcomes Research},
  doi = {10.2147/ceor.s567932},
  url = {https://doi.org/10.2147/ceor.s567932}
}

RIS

TY  - JOUR
TI  - Consequences of Canada’s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access
AU  - Nigel Rawson
PY  - 2025
JO  - ClinicoEconomics and Outcomes Research
DO  - 10.2147/ceor.s567932
UR  - https://doi.org/10.2147/ceor.s567932
ER  - 

APA

Rawson, N. (2025). Consequences of Canada’s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access. ClinicoEconomics and Outcomes Research. https://doi.org/10.2147/ceor.s567932

Source records